----
Current ValuationThe current P/E ratio is 38.88, above the reasonable range, cheaper than 18.46% of the time in the past 1 years, and the industry ranks 46/256, the industry Median -1.11.
38.88xP/E
$3.60Stock price
$0.09Earnings per share
38.88xP/E
Stock price$3.60Earnings per share$0.09
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.20x
- Typical range
- -4.56x–33.05x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0295887116
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
JNJUSJohnson & Johnson | 39.46x | 38.06% | $635.07B |
PFEUSPfizer | 39.49x | 18.73% | $171.16B |
RDYUSDr Reddys Laboratories | 36.80x | 12.04% | $11.00B |
LGNDUSLigand Pharmac-B | 30.68x | 14.01% | $6.05B |
IBOUSImpact BioMedical | 38.88x | -- | $30.76M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
